Nektar Stock: $400M Dilution And A Make-Or-Break Phase 3
Nektar stock has surged over 100% in a week and is now up a whopping 1,000% from its 52-week low of $6.50, trading around $71 as of February 13, 2026. The rally accelerated after the company released 36-week maintenance data from the REZOLVE-AD Phase 2b study for rezpegaldesleukin in atopic dermatitis. The data showed durable disease control—71% and 83% of patients maintained EASI-75 responses with monthly and quarterly dosing, respectively. This proves sustained efficacy over nine months.
The key question now is: Is NKTR stock a buy or a sell after this phenomenal rally? We believe it’s still worth pursuing. But before we dive into the details, individual stocks are unpredictable. A smart portfolio helps you invest, limits downside shocks, and provides upside exposure. Why settle for average market returns? The Trefis High Quality (HQ) Portfolio invests in a diverse group of 30 stocks that have collectively delivered stronger upside with reduced volatility compared to the broader indices. Discover the methodology behind these smoother, higher returns by checking the HQ Portfolio performance data.
What’s the market opportunity?
Atopic dermatitis affects approximately 30 million people in the United States. Sanofi’s Dupixent generated over $11 billion in 2024 sales, requiring injections every two weeks. Nektar’s data suggests comparable efficacy with quarterly dosing—a massive patient convenience advantage that could shift market share if replicated in Phase 3 trials.
- Pay Less, Gain More: GIB Tops Accenture Stock
- Stronger Bet Than CME Stock: MCO, SPGI Deliver More
- Why PTC Could Outperform Intuit Stock
- Better Value & Growth: GD, TDG Lead Lockheed Martin Stock
- Better Value & Growth: LTM Leads Southwest Airlines Stock
- Time To Buy The Dip In Dick’s Sporting Goods Stock?
What were the specific efficacy numbers?
At the 24 µg/kg dose level, 71% maintained EASI-75 with monthly dosing and 83% with quarterly dosing. For vIGA-AD 0/1 (clear or almost-clear skin), 85% maintained response with monthly dosing and 63% with quarterly. More impressively, EASI-100 response rates (complete clearance) increased up to 5-fold at week 52 compared to week 16. The drug keeps working over time rather than losing efficacy.
What about the expanded pipeline?
Rezpegaldesleukin is also being evaluated in Phase 2b trials for alopecia areata and in a Phase 2 trial for Type 1 diabetes mellitus. In December 2025, Nektar reported positive proof-of-concept data in alopecia areata, with the 24 µg/kg dose showing a 28.2% reduction in SALT scores versus 11.2% for placebo. The FDA has granted Fast Track designation for both atopic dermatitis and alopecia areata, potentially accelerating development timelines.
Multiple analyst upgrades signal strong conviction
BTIG raised its price target to $151 from $118, H.C. Wainwright increased theirs to $165 from $135, and William Blair upgraded Nektar from Market Perform to Outperform. The consensus average price target now stands at approximately $123, implying 70%+ upside from current levels.
What about the immediate dilution?
Nektar upsized its equity offering to $400 million (from an initially proposed $300 million), selling 6,603,449 shares at $58.00 per share. The offering closed on February 13, 2026. This represents approximately 30-35% dilution to existing shareholders. The proceeds will fund Phase 3 trials, manufacturing scale-up, and general corporate purposes.
What’s the cash runway?
With $270 million in existing cash plus $400 million from the new offering, Nektar has approximately $670 million. At current burn rates around $100-120 million quarterly, that provides roughly 15-18 months of runway. They’ll likely need additional financing before completing Phase 3 trials, which means more dilution ahead. Investors need to factor in multiple capital raises before potential commercialization.
How big could peak sales reach?
Dupixent proves this market supports multi-billion dollar products. Assuming Nektar captures 10-15% market share at peak with quarterly dosing convenience, peak sales could hit $1-2 billion annually across atopic dermatitis alone. Adding alopecia areata (affecting 700,000 people in the U.S. currently) could add another $300-500 million. But that’s 5-7 years out at a minimum—Phase 3 trials need to start, complete successfully, and FDA approval wouldn’t come until roughly 2029-2030.
What’s the valuation math?
Nektar’s market cap sits around $1.39 billion post-offering. Discounting $1.5 billion in peak sales back to today using a 10% discount rate and applying a 50% probability of Phase 3 success gives roughly $750 million NPV for just the atopic dermatitis indication. Add pipeline value (alopecia areata, Type 1 diabetes) and cash, and the valuation appears reasonable—not screaming cheap given the rally, but not wildly overvalued if Phase 3 succeeds.
What’s the binary risk?
Phase 3 failure. This was a 393-patient Phase 2b trial. Larger Phase 3 studies with more rigorous endpoints often show efficacy regressing to the mean. Safety issues could emerge at scale. If Phase 3 doesn’t hit its primary endpoint, expect a 50%+ stock drop.
Also, Nektar has negative operating margins and no revenue-generating products—they’re entirely dependent on clinical success.
What’s the market risk?
NKTR stock has historically performed worse than the S&P 500 during market downturns:
Inflation Shock (2022)
- NKTR stock fell 98.3% from a high of $381.90 on February 17, 2021 to $6.34 on November 28, 2023, vs. a peak-to-trough decline of 25.4% for the S&P 500
- The stock has since recovered dramatically to current levels around $70
- The highest the stock has reached post-crash is approximately $72 on February 12, 2026
COVID Pandemic (2020)
- NKTR stock fell 48.2% from $419.40 to $217.05, vs. a 33.9% decline for the S&P 500
- The stock eventually recovered
Global Financial Crisis (2008)
- NKTR stock fell 81.4%, recovering to pre-crisis levels by March 2010
Technical indicators suggest the stock may be overbought, with an RSI of 79.64 and a beta of 2.22 indicating high volatility. The stock could experience significant pullbacks from current levels.
Bottom line
If you are a long-term investor who can stomach large drawdowns and the binary risk of Phase 3 failure, NKTR stock has solid potential. The expanded pipeline beyond atopic dermatitis (alopecia areata and Type 1 diabetes) provides additional optionality. However, near-term catalysts are limited until Phase 3 initiation later in 2026, and further dilution is very likely. The average analyst price target of $123 implies another 70%+ upside, but given the recent 1,000%+ rally from lows and overbought technical conditions, near-term volatility and potential pullbacks should be expected. This is a high-risk, high-reward biotech bet that requires strong conviction in the science and ability to withstand significant volatility.
Real Wealth Is Built With Asset Allocation, Not Stock Picking
Don’t let short-term market noise derail your long-term goals. A professional wealth framework helps you stay disciplined, turning volatility into opportunity.
Are you positioned to outperform over the next 1-3 years? We analyzed whether adding allocations like 10% commodities and 10% gold to a standard stock-bond portfolio boosts returns. The results are clear: real assets matter. Our wealth management partner builds these robust portfolios to capture growth, while leveraging the Trefis High Quality Portfolio for superior stock selection.
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates